Literature DB >> 23588360

White matter disease: Early treatment of inflammatory demyelinating disease.

Naraporn Prayoonwiwat, Sasitorn Siritho.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23588360     DOI： 10.1038/nrneurol.2013.59

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

Review 1.  EFNS guidelines on diagnosis and management of neuromyelitis optica.

Authors:  J Sellner; M Boggild; M Clanet; R Q Hintzen; Z Illes; X Montalban; R A Du Pasquier; C H Polman; P S Sorensen; B Hemmer
Journal:  Eur J Neurol       Date:  2010-06-07       Impact factor: 6.089

2.  Brain abnormalities in neuromyelitis optica.

Authors:  Jee-Eun Kim; Sung-Min Kim; Suk-Won Ahn; Bung Chan Lim; Jong Hee Chae; Yoon-Ho Hong; Kyung-Seok Park; Jung-Joon Sung; Kwang-Woo Lee
Journal:  J Neurol Sci       Date:  2011-01-13       Impact factor: 3.181

Review 3.  Neuromyelitis optica.

Authors:  Mark J Morrow; Dean Wingerchuk
Journal:  J Neuroophthalmol       Date:  2012-06       Impact factor: 3.042

4.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Authors:  G Comi; M Filippi; F Barkhof; L Durelli; G Edan; O Fernández; H Hartung; P Seeldrayers; P S Sørensen; M Rovaris; V Martinelli; O R Hommes
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

5.  Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients.

Authors:  R Fazio; M L Malosio; V Lampasona; D De Feo; D Privitera; F Marnetto; D Centonze; A Ghezzi; G Comi; R Furlan; G Martino
Journal:  Mult Scler       Date:  2009-08-10       Impact factor: 6.312

6.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

7.  Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?

Authors:  Su-Hyun Kim; Woojun Kim; Xue Feng Li; In-Ja Jung; Ho Jin Kim
Journal:  Mult Scler       Date:  2012-02-21       Impact factor: 6.312

8.  A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).

Authors:  W M Carroll; T Saida; H J Kim; J Kira; A G Kermode; C P Tsai; K Fujihara; S Kusunoki; M Tanaka; K K Kim; D Bates
Journal:  Mult Scler       Date:  2013-01-16       Impact factor: 6.312

9.  Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies.

Authors:  J N Ratchford; M E Quigg; A Conger; T Frohman; E Frohman; L J Balcer; P A Calabresi; D A Kerr
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

10.  Attack-related severity: a key factor in understanding the spectrum of idiopathic inflammatory demyelinating disorders.

Authors:  Toshiyuki Fukazawa; Seiji Kikuchi; Masaaki Niino; Ichiro Yabe; Ryuji Miyagishi; Hikoaki Fukaura; Takeshi Hamada; Kunio Tashiro; Hidenao Sasaki
Journal:  J Neurol Sci       Date:  2004-10-15       Impact factor: 3.181
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.